Sevilla
save
The funding round opened by the Sevillian biotechnology Universal DX (UDX) It has exceeded all forecasts, since the company founded by Juan Martínez Barea has raised 14 million euros in 2020, four million more than initially planned. The round, covered by the company’s own shareholders, will allow the company to continue with its clinical trials, complete the colon cancer detection test this year with the intention of launching it on the market in 2022 with a reliability of more than 90% .
Created in 2012 in Seville, Universal DX has already raised 35 million euros: 30 million among private investors and 5 million euros in the public sector, since it raised funds
– .Related posts:
Training Methods for Lung Recovery and Improved Lung Function in Patients with Bacterial Pneumonia.
Drunk woman attacks federal police officers
They will apply a new vaccination program against Covid-19 in Durango - El Sol de Durango
HPV vaccine can prevent STDs and cancer!About the 5 QA of HPV Vaccine
